


Lung cancer

Average chemotherapy use by stage at diagnosis (2012–2017)



Australia

New South Wales



Canada

Ontario



British Columbia



Alberta



Saskatchewan



Manitoba




Nova Scotia



Norway

Norway



UK

England



Wales



Scotland



Northern Ireland



Stages 1–3
or localised
and regional

Stage 4
or distant

TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: Norway (12%); New South Wales (14%).

Lung cancer




Average chemotherapy use by stage at diagnosis (2012–2017):
stages 1–3 or local and regional




Australia


New South Wales




Canada



Norway



UK



TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: Norway (12%); New South Wales (14%).

'Overall average' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis.

Lung cancer




Average chemotherapy use by stage at diagnosis (2012–2017):
stage 4 or distant




Australia


New South Wales




Canada



Norway



UK



TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: Norway (12%); New South Wales (14%).



'Overall average' relates to the average chemotherapy use (%) across all jurisdictions included in the meta-analysis.

Lung cancer

Average chemotherapy use by TNM stage at diagnosis (2012–2017)



UK





Lung cancer

Average chemotherapy use by TNM stage at diagnosis (2012–2017)



Canada



*Fewer than 100 patients
Very small numbers may have been suppressed
in Prince Edward Island (stage 1).

Lung cancer



Average chemotherapy use by SEER stage at diagnosis (2012–2017)



Australia



Norway



Jurisdictions had a large % of missing stage data which could introduce bias: New South Wales (14%), Norway (12%).


Lung cancer

Average radiotherapy use by stage at diagnosis (2012–2017)



Australia

New South Wales



Canada

Manitoba



British Columbia



Newfoundland and Labrador



Alberta



Nova Scotia



New Brunswick



Saskatchewan



Ontario



Norway

Norway



UK

Northern Ireland



Wales



England



Scotland



Stages 1–3
or localised
and regional

Stage 4
or distant

TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: Northern Ireland (10%); Norway (12%); New South Wales (14%).

Lung cancer




Average radiotherapy use by stage at diagnosis (2012–2017):
stages 1–3 or local and regional



Australia

New South Wales



Canada

Newfoundland and Labrador

Ontario

Nova Scotia


British Columbia

Alberta

Manitoba


New Brunswick

Saskatchewan



Norway

Norway




UK

Northern Ireland

Scotland

Wales

England



TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: Northern Ireland (10%); Norway (12%); New South Wales (14%).

'Overall average' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.

Lung cancer




Average radiotherapy use by stage at diagnosis (2012–2017):
stages 4 or distant




Australia

New South Wales




Canada



Norway

Norway



UK



TNM and SEER stages do not always align: UK and Canada used TNM staging, Norway and Australia used SEER.

Some jurisdictions had a large % of missing stage data which could introduce bias: Northern Ireland (10%); Norway (12%); New South Wales (14%).

'Overall average' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.


Lung cancer

Average radiotherapy use by TNM stage at diagnosis (2012–2017)




UK


Northern Ireland




Wales




Scotland



England



0 20% 40% 60% 80% 100%



Some jurisdictions had a large % of missing stage data which could introduce bias: Northern Ireland (10%).


Lung cancer

Average radiotherapy use by TNM stage at diagnosis (2012–2017)




Canada


Newfoundland & Labrador




Ontario




Prince Edward Island




Nova Scotia




Alberta




Manitoba




British Columbia



New Brunswick



Saskatchewan



◆ Small numbers (between 1–9) were suppressed in Prince Edward Island (stage 2).

Lung cancer



Average radiotherapy use by SEER stage at diagnosis (2012–2017)



Australia



Norway



Jurisdictions had a large % of missing stage data which could introduce bias: New South Wales (14%), Norway (12%).